pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·1d ago·1 min read
save

Rising employer health premiums pressure workers as industry resists change

Oct 29, 2026·read at STAT ↗Negative

Workers are currently choosing health plans for the upcoming year as average family premiums for employer coverage climb to $28,303 in 2026, a 28% increase over the past five years.

Employers continue to shoulder most of the premium cost, but employees ultimately feel the burden through reduced wages, and there is little organized resistance to the rising expenses.

Key players in the system-insurers, brokers, hospital networks, fee‑for‑service physicians, and drugmakers-have strong financial incentives to maintain high prices, limiting appetite for reform.

Price disparities are evident even for identical procedures; an MRI or knee replacement can cost several times more at one hospital than another in the same city, highlighting the lack of pricing consistency.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: Health care needs buyers willing to say no”

read at STAT ↗
1,250 words · retrieved 1d ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Disc Medicine, Inc.LILLYMayo ClinicRISING
drugs
OzempicWegovyiron
topics
Cell TherapyDermatologyGene Therapy (AAV)Immunology

related stories

  • 1d agoSTAT+: Lilly’s triple-G drug beats Ozempic in head-to-head studySTAT
  • 2d agoSTAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes studySTAT
  • 2d agoSTAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technologySTAT
  • Aug 28STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Dec 22Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series AFierce Biotech